Romosozumab Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 105 mg/1.17 mL
Reference Brands: Evenity (USA/EU)
Category:
Osteoporosis
Romosozumab is a monoclonal antibody used for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. It works by inhibiting the protein sclerostin, which increases bone formation and decreases bone resorption. Romosozumab is administered as a monthly subcutaneous injection and helps improve bone density and reduce fracture risk.
Romosozumab is available in injection (prefilled syringe)
and strengths such as 105 mg/1.17 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Romosozumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Romosozumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing